ResearchResearch
- World leader in structure and fragment-based drug discovery
- Fully integrated structural biology with medicinal chemistry
- Excellent track record for innovation and delivery
- Collaborations with Novartis, Servier, GSK and Lundbeck
Vernalis is a world leader in structure and fragment-based drug discovery, with an excellent track record for innovation and delivery of clinical candidates in a range of therapeutic areas. Our internal research is currently aimed at discovering novel anti-cancer therapies by targeting cancer metabolism and cancer-specific synthetic lethality relationships.
Fragment- and Structure-Based Drug Design
Complementary methods of drug discovery
We are equally adept at both disciplines
Collaborations
We work well in partnership
Especially when we partner with companies like these
Publications
Regularly featured in scientific journals
See the latest articles we've published
Latest News
Tuesday, 17 January 2012
Vernalis and Servier Sign Third Oncology Collaboration
Vernalis plc, Servier announce they have entered into a new three-year joint oncology collaboration focused on the discovery of drugs for a new undisclosed target.
Product Pipeline
See at a glance what Vernalis has in development